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Highlights: 
 The availability of large public datasets for research interrogation presents great
opportunities to the multimorbidity community
 The advent of Health Data Science and machine learning as mature disciplines provide the
mechanics to ask novel questions of deterministically or probabilistically linked data
collections
 However, the complexity and depth of data about individuals often means that assuring
anonymity can be a challenge
 There is a large body of relevant legislation and information governance requirements of
which data processers need to be aware
 Similarly, data curation of generic datasets is an important consideration in the development





The interrogation of established, large-scale datasets presents great opportunities in health 
data science for the linkage and mining of potentially disparate resources to create new 
knowledge in a fast and cost-efficient manner. The number of datasets that can be queried in 
the field of multimorbidity is vast, ranging from national administrative and audit datasets, 
large clinical, technical and biological cohorts, through to more bespoke data collections 
made available by individual organisations and laboratories. However, with these 
opportunities also come technical and regulatory challenges that require an informed 
approach. In this review, we outline the potential benefits of using previously collected data 
as a vehicle for research activity. We illustrate the added value of combining potentially 
disparate datasets to find answers to novel questions in the field. We focus on the legal, 
governance and logistical considerations required to hold and analyse data acquired from 
disparate sources and outline some of the solutions to these challenges. We discuss the 
infrastructure resources required and the essential considerations in data curation and 





Multimorbidity affects approximately two-thirds of people aged over 60 years (Fortin et al., 
2012; Mokraoui et al., 2016), with complex interactions between education, behaviour, socio-
economic deprivation, and frailty contributing to disease risk (Marengoni et al., 2011; Vetrano 
et al., 2019). Interactions between diseases may be tracked at the individual and population 
levels, with the metabolic syndrome and osteoarthritis as common exemplars (Anderson and 
Felson, 1988; Saklayen, 2018). The advent of data science (the methods of recording, storing, 
and analysing data to effectively extract useful information), commensurate with our capacity 
to manage data at scale that has increased exponentially since 2000 (Hilbert and Lopez, 2011), 
has led to an explosion in the discovery of such disease interactions in recent years using data 
mining, deep learning and big data technologies (Galetsi and Katsaliaki, 2020).  
Here, the term “big data” is used to describe the study and applications of datasets that are 
too complex for traditional data-processing application software to adequately deal with 
(https://www.sas.com/en_gb/insights/big-data/what-is-big-data.html). The data may be described 
as “big” because of its volume, velocity (rate of accrual) or variety of formats (Figure 1). The 
development of this field provides a great opportunity in the multimorbidity domain to gain 
insights for patient benefit through the linkage and efficient analysis of large and 
complementary datasets (Burstein et al., 2019; Pawar et al., 2020). In this review, we consider 
the types of data that are commonly recorded, with some examples of their application in the 
multimorbidity setting. We describe the governance frameworks that control access to, and 
terms of use for large datasets. Our reference point is legislation that is applicable in the 
European Union and United Kingdom, but similar regulatory arrangements apply in most 
other countries. We also and outline the infrastructure requirements for managing these data 
and describe briefly some of the computational approaches used for their analysis. 
Why study pre-existing datasets? 
Reutilisation of previously collected data provides a highly cost-effective use of resources. 
Large datasets may provide national coverage for a particular disease area, and thus a broad 
geographic picture of disease incidence or prevalence and of the association between input 
variables and endpoints. Routinely collected data, whether for administrative or other 
purposes, provides real-world information at scale, and thus can provide insights into a given 
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disease that are generalisable to other populations of similar structure. Because participation 
is typically passive, in that the data are often collected without the requirement for individual 
consent, such large-scale datasets are, by their nature, inclusive and heterogeneous.  
Despite the advantage of scale, routinely collected data is also typically observational in 
nature. The data are not collected to answer a specific hypothesis, and may suffer from 
various sources of bias depending upon the population structure and the planned analysis 
application. The results of analysis of such datasets are inferential by association rather than 
causation, and thus hypothesis-generating in nature rather than hypothesis-solving. Various 
approaches may be taken to minimise the biases associated with routinely collected datasets 
or to infer causation, such as propensity score matching, Mendelian randomisation (a natural 
experiment design), or advanced regression techniques. A detailed consideration of their 
relative merits is, however, beyond the scope of this review. In contrast, data from clinical 
trials of an intervention used to demonstrate causation may also be made publically-available 
for secondary analysis. These data may be free from bias in respect of the intervention from 
which they were generated, but can lack generalisability because of the trial’s particular 
design and inclusion and exclusion criteria (Jaeschke and Guyatt, 1989).  Clinical trials are also 
typically of fairly short duration or rely on short term surrogate markers rather than real 
clinical endpoints, and use an intervention to which the participants are prepared to be 
randomised.  
What types of dataset are available? 
The types of data sources that may be integrated into modern analytical frameworks is limited 
mainly by data readability (format) and computational capacity. In the healthcare domain, 
data may be recorded digitally for several purposes. At the local level, electronic health 
records provide individual patient data for the purposes of direct patient care. Summary data 
of care episodes may be collected for administrative purposes, such as for billing or for 
resource management. These data may also be collated at regional or national level for 
administrative purposes and to audit patterns of disease or a healthcare system.  
Datasets may be classified by the sector from which they are generated. Population registers, 
such as the National Population Database in the UK, record geographic and demographic data 
including birth, death, education, and occupational data. A list of UK government accessible 
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datasets can be found at https://ckan.publishing.service.gov.uk/dataset. Health registers may be 
general (for example, the Clinical Practice Research Dataset), disease-specific (for example 
stroke, cancer or ischaemic heart disease), or intervention-specific (for example, joint 
replacement registers). Social care datasets may be identified through query to local, regional 
or national governmental organisations. In the United Kingdom, a national repository of 
health and care datasets can be accessed through NHS-Digital (https://digital.nhs.uk/data-
and-information/data-collections-and-data-sets/data-sets), the Healthcare Quality 
Improvement Partnership (HQIP https://www.hqip.org.uk/a-z-of-nca/) or local government 
through the relevant application process. In these types of dataset, the available resource is 
generic in nature, intended for a broad range of possible applications. Data may also be 
collated specifically for research purposes. Research datasets may include clinical information 
(patient characteristics), biological information (such as assay results and genomics data), or 
technical information and meta-data (for example imaging and other complex physical 
datasets). An example of a broad-purpose research data collection at scale is the UK Biobank 
https://www.ukbiobank.ac.uk/. Examples of more focussed research collections aimed at 
specific disease areas include the Osteoarthritis Initiative (https://oai.epi-ucsf.org/datarelease/) 
and the Framingham Heart Study (https://framinghamheartstudy.org/) in the United States. 
What can public datasets tell us about multimorbidity? 
There are many examples of the use of linked datasets to better understand the relationships 
between different risk factors and disease susceptibility, patient care and outcomes. For 
example, Wolff et al (Wolff et al., 2002) used Medicare and death data to demonstrate that 
in 1999, 82% of beneficiaries had 1 or more chronic condition and 65% had multiple chronic 
conditions. They also demonstrated the exponential increase in hospitalisations and cost to 
society associated with increasing numbers of co-existent conditions ($211 for those with no 
chronic conditions versus $13,973 for those with 4 or more). In primary care, Barnett et al 
(Barnett et al., 2012) used a national primary care clinical informatics dataset to show that 
the onset of multimorbidity occurs earlier in people living in the most deprived areas versus 
those most affluent, with socioeconomic deprivation particularly associated with 
multimorbidity that included mental health disorders. The presence of a mental health 
disorder increased as the number of physical morbidities increased, and was much greater in 
more deprived than in less deprived people.  
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In the case of specific disease components within multimorbidity and care, Morris et al 
(Morris et al., 2019) recently linked Hospital Episode Statistics (HES) and data from the 
Sentinel Stroke National Audit Programme (SSNAP) data to examine the effect of service 
centralisation in stroke treatment in Greater Manchester and found that hub and spoke 
models of care were effective at improving patient outcomes. Likewise, Hall et al (Hall et al., 
2016) examined national cardiac data from the Myocardial Ischaemia National Audit Project 
to profile the characteristics associated with hospital use of primary percutaneous coronary 
intervention, identifying inequities in provision, with older and sicker patients less likely to 
receive this treatment and inter-provider variation that was not explained by confounding 
factors. In musculoskeletal disease, Smith et al (Smith et al., 2017) used National Joint Registry 
(NJR) data linked to HES to identify differences in the rate of joint replacement in England by 
ethnic group and found these were lower in black and Asian people versus white people, 
highlighting a need for further work to examine whether these differences were driven by 
clinical factors or by cultural or access provision between the groups. On a similar theme, 
Bhimjijani et al used the National Hip Fracture Database (NHFD) and HES to demonstrate the 
persisting effect of social deprivation on fragility fractures of the hip between 2001 and 2015. 
Metcalfe et al (Metcalfe et al., 2019) linked the NJR, NHFD and HES to examine differences in 
outcome between patients undergoing hemiarthroplasty surgery versus those having a total 
hip replacement after neck of femur fracture, finding a higher rate of dislocation and a lower 
rate of revision in the group having total hip surgery. There is also published evidence of the 
effect of linking national audit data with other datasets to examine nursing care (Johansen et 
al., 2017a), anaesthesia (Johansen et al., 2017b), geriatric medicine (Neuburger et al., 2017) 
and surgery (Aitken et al., 2020) (Boyd-Carson et al., 2020)). 
What are the legal and governance requirements for data access? 
Accessing routinely collected data for secondary purposes typically requires a series of 
permissions to be put into place through data request to the scientific leads of the dataset 
manager, the data controller (who may be different to the manager) and the controllers of 
any data sources that the dataset will be linked with. Where personal data are to be 
processed, the legal bases under common and statutory law need to be established. This may 
involve patient consent or application to a national government authority, such as the 
Confidentiality Advisory Group in England (https://www.hra.nhs.uk/approvals-
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amendments/what-approvals-do-i-need/confidentiality-advisory-group/) for a consent waiver. 
Researchers may require access to data that cannot be fully anonymised, either because a 
specific level of granularity is required to support the intended analysis or because they intend 
to link the data at a record level with other health datasets.  
Much of the legal framework that governs the access to clinical datasets relates to the 
processing of personal data (Figure 2). For the most part, national data collection will capture 
data under the relevant data protection legislation. In the European Union this comprises the 
General Data Protection Regulation (GDPR, https://gdpr-info.eu/) ordinarily using the legal 
basis of a task in the public interest (Section 6.1.e) and reason of public interest in the area of 
public health (Section 9.2.i). Secondary users of the data may also use this legal basis if they 
can establish a relationship with a public authority, but may also rely on legitimate interests 
as a lawful basis under the law. 
Fully anonymous, aggregate data is out of scope of the GDPR. Anonymous data, as defined by 
the Data Protection Act 2018 as “information which does not relate to an identified or 
identifiable natural person or to personal data rendered anonymous in such a manner that 
the data subject is not or no longer identifiable” 
(http://www.legislation.gov.uk/ukpga/2018/12/contents/enacted). Where the link between the 
datasets of interest is already established and the dataset appropriately anonymised, access 
for third party researchers does not usually required ethics approval or a consent waiver.  
Alongside the legal basis that governs the original collection, an application for using the data 
for a secondary purpose must also consider the legal basis that their own project operates 
under and the necessary data flows (Figure 3). For example, does the consent model of the 
original data collection permit and secondary use? And if it does, would this include a flow of 
identifiable data to allow linkage, or just pseudonymised or anonymised data? In some cases, 
secondary users need to establish a de novo legal basis under common law, either by re-
consenting the subjects or by making a project-specific application to the relevant regulatory 
authority (CAG in the UK) for exemption under the regulations. Where necessary to preserve 
anonymity from the research team, a trusted third party may be used to establish the links 
between the datasets to enable analysis to be performed. 
8 
 
Alongside information governance considerations, access to controlled datasets require 
consideration of data security. Whilst robust organisational policies or procedures will 
underpin a credible approach to data security, data controllers require additional assurances 
by way of accreditations. In England, the national Data Security and Protection Toolkit serves 
as an auditable self-assessment of an organisation’s information security compliance, 
although use of this is typically by public sector organisations. Other formal accreditations 
include CyberEssentials (https://www.ncsc.gov.uk/cyberessentials/overview) and ISO27001 
(https://www.iso.org/isoiec-27001-information-security.html).  
The complexity of these requirements should not be underestimated and success at accessing 
datasets requires careful planning and expert advice from information governance 
professionals. Data controllers are increasingly trying to reduce this burden by use of software 
solutions such as DataShield (Wallace et al., 2014) or OpenPseudonymiser 
(https://www.openpseudonymiser.org/) that allow the linkage of datasets without the transfer 
of identifiers. Similar solutions have been used to great effect in the SAIL database (Jones et 
al., 2014) in Wales. It is also sensible to explore solutions where data is accessed by applicants 
on a secure portal, removing the need to release datasets directly to applicants and thus 
reducing the risk of breach and harmonising information security declaration requirements 
to the regulator.  
Infrastructure requirements 
The analysis of large and complex datasets requires a suitable supporting hard and soft 
infrastructure.  The hard infrastructure includes the technologies necessary for large-scale 
data analysis e.g. data storage, processing power and capacity, software systems and tools 
for analysis.  The soft infrastructure includes the technical services to support the hard 
infrastructure, and the skills (research domain knowledge and analytical) needed to 
undertake valid and meaningful analysis. 
High Performance Computing facilities within a trusted research environment (TRE) are 
essential for the storage and analysis of large-scale datasets. A TRE is certified data storage 
environment that provides strict security controls to prevent unauthorised access and 
misuse of data.  This infrastructure may take the form of standalone computing facilities 
within the institution or a shared data and analytics infrastructure within a collaborating 
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partnership. An example of the latter is The Greater Manchester Datawell 
(https://www.connectedhealthcities.org/2016/09/what-is-the-datawell/), a health and care 
repository that captures the city’s population to enable data sharing for research.   
In recent years, cloud computing has become an increasingly used efficient and cost-
effective approach to the delivery of the hardware infrastructure requirements. Cloud 
computing refers to the provision of remote computing services – storage, processing and 
network systems, via an internet access point. These services can be public or organisation 
specific and reduce the requirement for computationally and resource intensive server 
capacity to be retained by research teams or data controllers. Typically, these solutions are 
also adaptive, making additional server space or processor capacity available on demand. 
Commercially available cloud services are increasing being used for access, storage and 
operation of big datasets. When adopting cloud based solutions, it remains important that 
the security and legal infrastructure of the physical servers are assured.  
A third party approach data access, processing and analysis is to use a remote computing 
solution that does not require any investment in hard infrastructure. In this model the 
researcher achieves access to the data through a remote device with appropriate security 
controls. The NJR Data Access Portal (NJR DAP https://portal.njrdap.njrcentre.org.uk/) is an 
example of such a remote data access and analysis portal. The NJR DAP is hosted on a 
virtualised environment within a secure data centre.  Access to the system is via a virtualised 
private network using remote desktop tools that provide the necessary encrypted 
communications between the system and the remote user and, through configuration of the 
remote desktop tools, ensure that the data and the system are protected from misuse (e.g. 
preventing the unauthorised upload or download of files by users). The physical 
infrastructure is completely isolated behind a firewall that only permits access to the 
remote desktop. Figure 4 illustrates the physical components making up the NJR Research 
Environment.  Physical separation of the service architecture in this way increases the level 
of security, separating NJR data from the outside world.  
Although the appropriate technical infrastructure is crucial to support access to an analysis 
of datasets, it is also important that the contractual infrastructure under which the 
technology is developed is robust, incorporates version control, and facilitates time-
registered audit of the data access and analysis. These processes allow data controllers and 
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analytical teams to be assured of the security of the data and the availability of sufficient 
computational capacity to reliably run analytical routines. Where datasets are released 
directly to an analytical team, these responsibilities rest entirely with the receiving 
organisation and careful consideration of the security setup and support arrangements is 
required. Remote solutions via a data access portal provides these arrangements on behalf 
of the analytical team, but there is still be a requirement for reliable, controlled access to 
the secure environment. 
The tools available for analysis will vary according to the preferences of the analysis teams, 
but software including STATA, R and Python are all widely used. These tools vary in 
sophistication and will require users to be familiar with the code or structure required for 
the input. Where an analysis platform is provided remotely by the dataset controller, the 
choice of tools available may be limited due to licensing considerations. For example, in the 
NJR DAP, the research ready data that the infrastructure hosts is created annually and the 
software included for use by users comprises Office, R, Python, and Stata. However, 
safeguards are required to ensure that any data exported from the portal does not include 
source data. This can be easily achieved using a quarantine approach for automated or 
manual inspection before download permission request is granted. 
Data curation and analysis 
When data is collected at scale, it is likely that there will be inconsistencies in the recording 
of data, missing fields and records and general untidiness. Datasets may also be revised and 
evolved over multiple iterations with subtle differences emerging in the resultant data. It is 
important that those wishing to analyse these datasets are sufficiently familiar with the 
underlying dataset design to be able to model for these inconsistencies. Equally important is 
inclusion in analytical teams of specialist clinicians in order to give a front line perspective on 
how data reporting rules may have been interpreted by clinical teams at the point of 
collection. Data curation describes the process of turning independently created data sources 





Data quality is a key consideration in determining the utility of a dataset for a given analytical 
purpose or for linkage with other datasets. These attributes are the data accuracy, coverage, 
and completeness. Accuracy is a measure of the correctness of the data within each data cell. 
Coverage describes the proportion of the total population that is captured by the dataset. 
Completeness refers to the rate at which individual data points are missing from the dataset. 
Systematic biases in any of these three domains will affect the validity of inferences made 
from the data. For example, if data is missing from a defined geographic region or due to a 
batch effect, then analysis results may not be generalisable to that section of the population, 
and if data on a particular attribute is missing in a non-random manner, then this will bias the 
results of dependent analyses. 
Data format. Data may be made available as summary statistics that describe aggregated 
information about the characteristics of a group of individuals for a particular attribute of 
interest. An example of this may be population mean age and a measure of the distribution, 
or sex distribution within a given population. This type of data, by its nature, is anonymised 
(provided the sample size is sufficiently large) but has limited utility for examining interactions 
between variables and their effects. Data may also be made available at the individual level. 
In this case, data-points are mapped to the individual person, allowing relationships between 
variables to be explored at depth.  
Data pre-processing includes: 1) Cleaning (dealing with missing values, data outliers, and 
resolving duplication or inconsistencies); 2) Integration (combining of multiple databases or 
individual level files; 3) Data transformation to a common format (normalisation and 
transformation) so that it is ready for analysis. The process requires that all the data are 
formatted to a common library of language rules and definitions to facilitate the analysis. This 
pre-processing can be challenging when applied to routinely collected clinical records, 
including missing or inconsistently recorded information (Peek and Rodrigues, 2018).  
Data linkage is the process of linking data from different sources. The utility of a dataset may 
be characterised by its likability to other datasets to create a new layer of unique information. 
Data linkage can substantially augment the value of participating datasets, not simply by 
providing additive information, but by opening up new avenues and scale of investigation.   
However, if done incorrectly can result in bias in the linked data (Harron et al., 2017).   
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Data linkage may be undertaken using a deterministic or probabilistic approach. In the 
deterministic approach, the datasets are linked by set of unique identifiers that are common 
across the datasets being linked. In this instance, subject A in dataset 1 is only linked with the 
other dataset(s) if there is a full match of the chosen identifiers (for example full name, date 
of birth, sex, address, and social security number) across the datasets. The alternative 
approach to linking is probabilistic (or fuzzy) linkage. In this approach a wider range of 
potential identifiers is used, computing weights for each identifier based on its estimated 
ability to identify a correct match for a given individual across the datasets. The threshold at 
which a record matches between the datasets is thus a function of statistical probability for 
which a threshold is defined, according to the rigour required by the analyst. Deterministic 
linkage thus follows a pre-defined rules based approach whilst probabilistic linkage allows 
greater flexibility for automation and speed that is balanced against the requirement for 
linkage accuracy. The speed and accuracy of probabilistic linkage has been enhanced in recent 
years by the application of machine learning approaches including neural networks and 
natural language processing (Tucker et al., 2019). 
Data analysis. A detailed review of the analytical approaches used in health data science is 
outside of the scope of this article. However, expertise in big data methodologies is required 
to successfully link, process and analyse health informatics datasets of the scale outlined 
above. These  skills include, but are not limited to: Management of different scale within the 
data (high volume low density / low volume high density; versatility with a variety of 
computational skills including machine learning, bioinformatics, natural language processing 
and computational linguistics; as well as more traditional statistical analysis techniques. 
Summary and conclusions 
Here we have given an overview of the opportunities and challenges that are faced when 
using and combining large public datasets to answer questions in multimorbidity. We have 
focussed on the legislation and resources required as they apply to the United Kingdom and 
the European Union, although similar principles apply elsewhere. We have highlighted some 
of the available opportunities, focussing on public datasets, where the challenges of volume, 
velocity and variety are more pronounced than in technically or biologically curated datasets 
that are prepared with research as their primary purpose. The publications referred to in the 
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field are not intended to present exemplars, but are illustrative of the variety of opportunity 
available to the field through embracing big data. 
 
Legend to figures 
Figure 1. What is “Big Data”? 
Figure 2. Key legislative areas that govern access to public datasets requiring linkage within 
the United Kingdom and European Union 
Figure 3. Example data flows for linkage project using multiple datasets 
Figure 4. Schematic representation showing the key elements of the NJR Data Access Portal, 
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